OPTHEA LIMITED ORDINARY (OPT) Short Interest
OPTHEA LIMITED ORDINARY (ASX:OPT) had 0.31% of shares reported as short positions as of 26 June 2026, representing 4,299,432 shares. OPTHEA LIMITED ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
OPT
Opthea
Opthea is a biopharmaceutical company focused on developing innovative biologics-based therapies for treating vision-threatening eye diseases. The company is pioneering the development of sozinibercept, a first-in-class VEGF-C/D 'trap' inhibitor, aimed at improving treatment outcomes for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).